

Therapeutic Use of Mechanical Ventilation: Can We Change the Way We Manage the Patient?

*2014 Suncoast Pulmonary Symposium
Hyatt Regency Coconut Point Resort
Bonita Springs, Florida
September 10-12, 2014*



Gary F. Nieman

Associate Professor

Department of Surgery

Director,

Cardiopulmonary and Critical Care Laboratory

SUNY Upstate Medical University

Syracuse, NY

Niemang@upstate.edu

Why is it Important to Prevent ARDS?

- Once established ARDS is very difficult to treat
 - Almost all clinical trials a failure (MacIntyre & Brower)
 - Low Vt only reduced ARDS moderately (ARDSnet)
 - Mortality of ARDS still 30-60% (Shari & Herridge)
 - Mortality is higher than Breast Cancer (Rubenfeld)
 - **Even with Low Vt mortality still >40%** (Villar ALIEN Study)
- Patients that develop established-ARDS often develop chronic lung and brain injury

Thirty years of clinical trials in acute respiratory distress syndrome

Robert C. McIntyre Jr, MD; Edward J. Pulido, MD; Denis D. Bensard, MD; Brian D. Shames, MD;
Edward Abraham, MD, FCCM

(Crit Care Med 2000; 28:3314–3331)

Established-ARDS: Difficult to Treat

Table 2: ARDS Treatments, Evidence & Recommendations Systematically Reviewed	Adapted from Ware et al [1] and Cepovka et al [2]	
Treatment Modality	Evidence Level	Recommendation Grade
Ventilatory		
-Low Tidal Volume	1 & 2	B
-Open Lung	2	B
-Inverse Ratio	3 & 4	D
-Liquid Ventilation	4	E
Extracorporeal Life Support	Level 1 & 2 <i>Against</i>	Not Recommended
Prone Positioning	3	D
Restrictive Fluid Management	2	C
	3	C
	Level 1 <i>Against</i>	Not Recommended
-Almitrine	3	C
-Prostacyclin	3	C
	Level 1 <i>Against</i>	Not Recommended
-Ketoconazole	Level 1 <i>Against</i>	Not Recommended
-Ibuprofen	Level 2 Mixed Results	Not Recommended At Any Level
-Corticosteroid	2	C
-N-acetylcysteine	Level 2 Mixed Results	Not Recommended At Any Level

ARDS: 14

The Good Guys: 1

Ouch..

Established-ARDS: Difficult to Treat

TABLE 1. SELECTED RANDOMIZED CONTROLLED CLINICAL TRIALS IN ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME*

	Year	No. Patients	Intervention	Clinical Outcome Result*
Surfactant trials				
Weg (27)	1994	51	Exosurf—aerosolized	NSD
Anzueto (11)	1999	725	Exosurf—aerosolized	NSD
Gregory (14)	1997	59	Bovine surfactant—endotracheal instillation	NSD
Spragg (13)	2004	448	Protein C surfactant—endotracheal instillation	NSD
Kesecioglu (12)	2009	418	HL 10 surfactant—endotracheal instillation	NSD
Spragg (1)	2011	843	Protein C surfactant—endotracheal instillation	NSD
Other trials				
Zapol (18)	1979	90	ECMO	NSD
Amato (2)	1998	53	Lower tidal volume + higher PEEP	Protective approach better
Stewart (28)†	1998	120	Lower tidal volume/inspiratory pressure	NSD
Brochard (29)	1998	116	Lower tidal volume/plateau pressure	NSD
Brower (30)	1999	52	Lower tidal volume/plateau pressure	NSD
Abraham (17)	1999	350	Prostaglandin E1	NSD
ARDS Network/Steinberg (31)	2000	234	Ketoconazole	NSD
ARDS Network/Brower (3)	2000	861	Lower tidal volume/plateau pressure	Tidal volume better
Gattinoni (32)	2001	304	Prone position	NSD
ARDS Network/Abraham (19)	2002	235	Lisofylline	NSD
Derdak (33)	2002	148	High frequency oscillatory ventilation	NSD
Taylor (16)	2004	385	Inhaled nitric oxide	NSD
ARDS Network/Brower (34)	2004	549	Higher PEEP	NSD
Kacmarek (35)	2006	311	Partial Liquid Ventilation	NSD
Mancebo (36)	2006	136	Prone positioning	NSD
ARDS Network/Steinberg (37)	2006	180	Methylprednisolone for persistent ARDS	NSD
ARDS Network/Wiedemann (38)	2006	1000	Fluid-conservative hemodynamic strategy	NSD‡
ARDS Network/Wheeler (39)	2006	1000	Pulmonary artery vs central venous catheter	NSD
Villar (4)	2006	95	Lower tidal volume + higher PEEP	Lung-protective approach better
Meduri (8)	2007	91	Methylprednisolone for early ARDS	Methylprednisolone better
Mercat (40)	2008	767	Higher PEEP	NSD
Meade (41)	2008	983	Higher PEEP	NSD
Taccone (42)	2009	342	Prone positioning	NSD
Peek (9)	2010	180	Transfer to ECMO-capable center	Transfer better
Papazian (10)	2010	340	Neuromuscular blockade	Neuromuscular blockade better

Definition of abbreviations: ALI = acute lung injury; ARDS = acute respiratory distress syndrome; ECMO = extracorporeal membrane oxygenation; NSD = not significantly different; PEEP = positive end-expiratory pressure.

Included trials enrolled at least 50 patients. Some trials with more than 50 patients were not included because they were pilot studies for subsequent trials.

* Results of primary outcome variable analysis.

† Patients at risk for ALI.

‡ Ventilator-free days (secondary outcome variable) was significantly greater in the fluid-conservative group.

Recently Failed Trials

Randomized, Placebo-controlled Clinical Trial of an Aerosolized β_2 -Agonist for Treatment of Acute Lung Injury

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network

Am J Respir Crit Care Med Vol 184. pp 561–568, 2011

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Preclinical studies and one clinical trial suggested that β_2 -agonist therapy could reduce pulmonary edema in acute lung injury. However, the potential value of aerosolized β_2 -agonist therapy for treatment of acute lung injury has not been tested previously in a phase III, randomized clinical trial.

What This Study Adds to the Field

The results of this randomized double-blind clinical trial demonstrate that aerosolized β_2 -agonist therapy with albuterol did not improve clinical outcomes in patients with acute lung injury.

Recently Failed Trials

Recombinant Surfactant Protein C–based Surfactant for Patients with Severe Direct Lung Injury

Roger G. Spragg^{1*}, Friedemann J. H. Taut^{2*}, James F. Lewis³, Peter Schenk⁴, Clemens Ruppert⁵, Nathan Dean⁶, Kenneth Krell⁷, Andreas Karabinis⁸, and Andreas Günther⁵

Am J Respir Crit Care Med Vol 183. pp 1055–1061, 2011

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Prior studies have suggested that treatment with exogenous surfactant of patients with severe direct lung injury may be beneficial.

What This Study Adds to the Field

In this prospective, blinded, randomized study of 843 patients, delivery of a recombinant surfactant protein C–based surfactant provided no benefit to patients with severe direct lung injury.

Recently Failed Trials

The NEW ENGLAND JOURNAL of MEDICINE

2013

ORIGINAL ARTICLE

High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome

Niall D. Ferguson, M.D., Deborah J. Cook, M.D., Gordon H. Guyatt, M.D.,

CONCLUSIONS

In adults with moderate-to-severe ARDS, early application of HFOV, as compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure, does not reduce, and may increase, in-hospital mortality. (Funded by the Canadian

No Reduction in ARDS Mortality since 1998




FIGURE 1. Schematic representation of average reported mortality in observational and randomized controlled trials in adult patients with acute respiratory distress syndrome since 1967. Data have been compiled from [6[■],11,12[■],26,27[■]].

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What kind of mechanical breath is necessary to prevent ARDS?


To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What kind of mechanical breath is necessary to prevent ARDS?


T/HS/S




Systemic Inflammation




+
VILI



ARDS



Intubation





Is acute respiratory distress syndrome an iatrogenic disease?

Jesús Villar^{1,2,3} and Arthur S Slutsky^{*3,4,5}

Critical Care 2010, 14:120

- “..should we begin to consider that ALI/ARDS is a consequence of our efforts rather than progression of the underlying disease?”
- “..injurious ventilation strategies have been shown to cause all of the pathology associated with ALI/ARDS.”
- “..ALI/ARDS is largely a ‘man-made’ syndrome.”
- “..ALI/ARDS is no longer a syndrome that must be treated, but is a syndrome that should be prevented.”

Improper Ventilation in 'Normal' Lungs Drives ARDS.




Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation*

Ognjen Gajic, MD; Saqib I. Dara, MD; Jose L. Mendez, MD; Adebola O. Adesanya, MD; Emir Festic, MD; Sean M. Caples, MD; Rimki Rana, MD; Jennifer L. St. Sauver, PhD; James F. Lymp, PhD; Bekele Afessa, MD; Rolf D. Hubmayr, MD

Crit Care Med 2004

Patients in the ICU without ALI placed on multiple Vt's



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


A Trial of Intraoperative Low-Tidal-Volume Ventilation in Abdominal Surgery

Emmanuel Futier, M.D., Jean-Michel Constantin, M.D., Ph.D.,
Catherine Paugam-Burtz, M.D., Ph.D., Julien Pascal, M.D.,
Mathilde Eurin, M.D., Arthur Neuschwander, M.D., Emmanuel Marret, M.D.,
Marc Beaussier, M.D., Ph.D., Christophe Gutton, M.D., Jean-Yves Lefrant, M.D., Ph.D.,
Bernard Allaouchiche, M.D., Ph.D., Daniel Verzilli, M.D., Marc Leone, M.D., Ph.D.,
Audrey De Jong, M.D., Jean-Etienne Bazin, M.D., Ph.D., Bruno Pereira, Ph.D.,
and Samir Jaber, M.D., Ph.D., for the IMPROVE Study Group*

N ENGL J MED 369;5 NEJM.ORG AUGUST 1, 2013

Non-protective Ventilation = V_t 10-12cc/kg 0 PEEP
Lung-protective Ventilation = V_t 6-8cc/kg, 6-8 PEEP + RM

Reduced Major Complications



Lower tidal volume at initiation of mechanical ventilation may reduce progression to acute respiratory distress syndrome: a systematic review

Brian M Fuller^{1*}, Nicholas M Mohr², Anne M Drewry³ and Christopher R Carpenter⁴

- Key Messages
 - Higher V_t are causal in the development of ARDS
 - ARDS occurs early in the course of mechanical ventilation suggesting that ARDS-prevention trials should occur early, such as in the emergency department
 - The development of ARDS is associated with significant increases in mortality and morbidity, suggesting that ARDS-prevention trials are needed

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- **Conclusion: MV plays a major role in ARDS pathogenesis**
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What are the key pathologic components that comprise pre-ARDS pathophysiology?


To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Conclusion: MV plays a major role in ARDS pathogenesis
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What kind of mechanical breath is necessary to prevent ARDS?

Timing of the Onset of Acute Respiratory Distress Syndrome: A Population-Based Study

Giath Shari MD, Marija Kojicic MD, Guangxi Li MD, Rodrigo Cartin-Ceba MD,
Cesar Trillo Alvarez MD, Rahul Kashyap MBBS, Yue Dong MD, Jaise T Poulouse MBBS,
Vitaly Herasevich MD, Javier A Cabello Garza MD, and Ognjen Gajic MD

Respir Care 2011;56(5):576–582.



86% of ARDS Develops in a Hospital

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
 - Most ARDS develops in the hospital so there is an opportunity to prevent
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What are the key pathologic components that comprise pre-ARDS pathophysiology?

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
 - Most ARDS develops in the hospital so there is an opportunity to prevent
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
- What are the key pathologic components that comprise pre-ARDS pathophysiology?



CHEST

Original Research

CRITICAL CARE MEDICINE

**Identification of Early Acute Lung Injury
at Initial Evaluation in an Acute Care
Setting Prior to the Onset of
Respiratory Failure***

*Joseph E. Levitt, MD, MS; Harmeet Bedi, MD; Carolyn S. Calfee, MD;
Michael K. Gould, MD, MS, FCCP; and Michael A. Matthay, MD*

(CHEST 2009; 135:936–943)

Early Acute Lung Injury (EALI): **Before** the patient is placed on MV

Early Acute Lung Injury (EALI) Criteria

- Admission with Bilateral infiltrates on CXR
- Initial O₂ requirement of >2L/min
- Strong predictor of patient progressing to ALI
 - 73% sensitivity
 - 79% specificity

ARDS Staging

- Once the patient progresses from EALI to ALI and is placed on mechanical ventilation the lung progresses through an additional 3-Stages of progressively increasing pathology









Acute Respiratory Distress Syndrome

The Berlin Definition

The ARDS Definition Task Force* *JAMA*. 2012;307(23):2526-2533
Published online May 21, 2012. doi:10.1001/jama.2012.5669

- Degrees of *ARDS*
 - Mild ARDS: $P/F \leq 300$ with $PEEP \geq 5$
 - Moderate ARDS: $P/F \leq 200$ with $PEEP \geq 5$
 - Severe ARDS: $P/F \leq 100$ with $PEEP \geq 5$

ARDS Pathogenesis

Stage	Column A	Column B	Column C
N			CLINICAL PARAMETERS: P/F <200: No Infiltrated X-ray: No Refractory Hypoxemia: No
1			CLINICAL PARAMETERS: P/F <200: No Infiltrated X-ray: No Refractory Hypoxemia: No
2			CLINICAL PARAMETERS: ▶ P/F <200: YES ▶ Infiltrated X-ray: YES Refractory Hypoxemia: No
3			CLINICAL PARAMETERS: P/F <200: YES Infiltrated X-ray: YES ▶ Refractory Hypoxemia: YES

EALI

Insidious-ARDS

Established-ARDS

What is *Insidious-ARDS* and is there proof that it exists?


Insidious-ARDS is an early stage of ARDS that is treatable and presents with the identical clinical *symptoms as does Established-ARDS*, however, with a maneuver such as a **FiO₂-PEEP Trial** oxygenation dramatically improves and the patient no longer meets AECC defined ARDS

Niall D. Ferguson
Robert M. Kacmarek
Jean-Daniel Chiche
Jeffrey M. Singh
David C. Hallett
Sangeeta Mehta
Thomas E. Stewart


Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial

- **Observation:** Patients with AECC defined ARDS have a P/F <200 *regardless of ventilator settings*
- **Intervention:** Screening these patients with standardized ventilator settings would identify *Persistent-ARDS*
 - Vt 7-8 ml/kg
 - PEEP 10 cmH₂O
 - FiO₂ 100%
- **Results:** *Persistent-ARDS* 42%; *Transient-ARDS* 59%
- **Conclusion:** This study supports the concept of a slow progressive pathogenesis for ARDS and suggests that preemptive application with the correct *Mechanical Breath* may be able to block disease progression

Insidious-ARDS



P/F ratio
<200



P/F ratio
>400

Insidious-ARDS

- Unlike pregnancy ARDS is not binary but rather a disease with a progressive, insidious onset, similar to cancer
- *Insidious-ARDS* presents with identical symptoms as does *Established-ARDS*
- However, if the proper Mechanical Breath is applied to the lung with *Insidious-ARDS* the lung will reopen, edema will be reduced and oxygenation will return and disease progression may be halted

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
 - *EALI* and *Insidious-ARDS* are progressive stages leading to *Established-ARDS*.
- What kind of mechanical breath is necessary to prevent ARDS?

To Prevent ARDS we must Understand the Pathogenesis

- What is the role of mechanical ventilation in the development of *Established-ARDS*?
- Is there a ‘treatment window’ in the hospital during which ARDS can be treated?
- What is the progressive pulmonary pathophysiology as *EALI* evolves into *Established-ARDS* ?
 - *EALI* and *Insidious-ARDS* are progressive stages leading to *Established-ARDS*.
- What kind of mechanical breath is necessary to prevent ARDS?


Before we can determine the components of the mechanical breath that may prevent the pathogenesis of ARDS we must know:

- The key pathologic components that drive progressive acute lung injury into ARDS
- Is the disease process propagated by a mechanical or inflammatory injury or both?

Before we can determine the components of the mechanical breath that may prevent the pathogenesis of ARDS we must know:

- The key pathologic components that drive progressive acute lung injury into ARDS
- Is the disease process propagated by a mechanical or inflammatory injury or both?

Pathologic Tetrad of ARDS




Appropriate
 P/T_p



Increased Capillary Permeability

Alveolar Edema



Alveolar Instability

Surfactant Deactivation

Before we can determine the components of the mechanical breath that may prevent the pathogenesis of ARDS we must know:

- The key pathologic components that drive progressive acute lung injury into ARDS
- Is the disease process propagated by a mechanical or inflammatory injury or both?

ALI Models and Inflammatory Mediators

Investigated Factor	PMN			Edema			Hypoxemia			Mortality			References	
	L	A	V	L	A	V	L	A	V	L	A	V		
Leukocytes														
AM (from depletion studies)						2								(1-4)
CD11/CD18	2	2			2									(5-8)
CXCR2														(9-11)
DARC														(12, 13)
Elastase	2	2	2		2	1:1								(14-19)
ICAM1	2													(5, 20, 21)
MMP8			1:1			1:1								(22-24)
NADPH oxidase														(25, 26)
PMN (from depletion studies)	2				2									(27-30)
ROS (antioxidants)														(28, 31-33)
Eicosanoids														
PLA2														(34, 35)
LTB4	1:1				1:1									(36-38)
LTC/D4														(39, 40)
Extracellular mediators														
ACE2, AT2														(41)
ACE, AT1			3:1			5								(42-47)
HMGB1	2				2									(48-51)
IL-6														(52, 53)
MIP-2/KC/IL-8	7:1	2			5	3		2						(56, 29, 36, 54-60)
TNF			1:1			2:1								(61-66)
PAF														(67, 68)
Stress-regulated genes														
JNK			2											(22, 69, 70)
p38														(71, 72)
PARP	2	2			2									(76-79)
GADD45														(80)
Singalling														
MLCK	2				2									(81, 82)
TLR4						2								(39, 52, 83)
cAMP (PDE4 inhibitors)						2		2						(84-87)
GR (steroids)	2:2				3:1									(31, 84, 88-91)

VILI

Acid Aspiration

Endotoxin - LPS

Grey = No effect

Yellow = Protective

Green = Contributing

Magenta = Contradictory

No Mortality Correlate!

Mechanical Injury During Ventilation

Stress/Strain

Lung Stress and Strain During Mechanical Ventilation: Any Difference Between Statics and Dynamics?

Alessandro Protti, MD¹; Davide T. Andreis, MD¹; Massimo Monti, MD¹; Alessandro Santini, MD¹; Cristina C. Sparacino, MD¹; Thomas Langer, MD¹; Emiliano Votta, PhD²; Stefano Gatti, MD³; Luciano Lombardi, RT⁴; Orazio Leopardi, MD¹; Serge Masson, PhD⁵; Massimo Cressoni, MD¹; Luciano Gattinoni, MD FRCP^{1,6}.


What is Stress/Stain Injury, Really?

- Mechanical Stress
 - High airway pressure/shear stress (Volu- Atelectrauma)
- Exceeding the limits of the support structure
 - Alveolar and bronchiole walls
- Causing serious damage
 - VILI

Mechanism of VILI


Mechanical Stress

Support Structure




Serious Injury


Study Protocol



Shear Stress-Induced Alveolar Injury



Direct Injury by VILI



Summary

- The 4 key pathologic components in ARDS pathogenesis are:
 - Increased capillary permeability
 - Surfactant deactivation
 - Alveolar edema
 - Alveolar instability (alveolar R/D)
- Mechanical damage caused by non-protective mechanical ventilation drives the progression of acute lung injury

Question

If mechanical ventilation is a primary driving force in progressive acute lung injury, how in the world can we use mechanical ventilation to prevent acute lung injury?

Take an Entirely New Approach

- Deconstruct the mechanical breath
 - Analyze all 10 components of the mechanical breath (pressures, flows, rates, volumes, *Times*)
 - Mechanical Breath Profile (MB_p)
- Determine the impact of any given MB_p on the Micro-environment – the alveoli and alveolar ducts


Take an Entirely New Approach

- Deconstruct the mechanical breath
 - Analyze all 10 components of the mechanical breath (pressures, flows, rates, volumes, *Times*)
 - Mechanical Breath Profile (MB_p)
- Determine the impact of any given MB_p on the Micro-environment – the alveoli and alveolar ducts

Whole Breath Deconstruction

- **Time** at Inspiration (T_I)
- Pressure at Inspiration (P_I)
- **Time** at Expiration (T_E)
- Pressure at Expiration (P_E)
- Transition Time from P_E to P_I (Inspiration rate - ΔP_I)
- Transition Time from P_I to P_E (Expiration rate - ΔP_E)
- Respiratory Rate
- Tidal Volume
- Inspiratory Flow
- Expiratory Flow
- FRC
- TLC

Whole Breath Deconstruction



First Step in Whole Breath Analysis

Identify the role of *Time* on lung protection

Pressure/Time Profile: P/T_p

Components Comprising the P/T_p

- Inspiration

– Time

– Pressure

P_{plat} < 30

- Expiration

– Time

– Pressure

↑ PEEP

CMV

- RATE of change between Inspiration and Expiration

Components Comprising the P/T_p

- Inspiration

- Time

T_{High}

- Pressure

P_{High}

- Expiration

- Time

T_{Low}

- Pressure

P_{Low}

APRV

The diagram illustrates the components of APRV. A central orange box labeled 'APRV' is connected by four orange lines to four other orange boxes: T_{High} , P_{High} , T_{Low} , and P_{Low} . These boxes are arranged in a 2x2 grid to the left of the central box. The top row contains T_{High} and P_{High} , and the bottom row contains T_{Low} and P_{Low} .

- RATE of change between Inspiration and Expiration

We used the APRV mode in our experiments due to the ease of setting the Time of pressure application throughout the mechanical breath


Ventilator as a Therapeutic Tool to Prevent ARDS

- Maintain a fully inflated homogeneously ventilated lung
 - APRV extended *time* at inspiration (T_{High}) continually recruits
- Prevent alveolar collapse during expiration
 - APRV very short *time* a expiration (T_{Low}) prevents collapse

Ventilator as a Therapeutic Tool to Prevent ARDS

- Maintain a fully inflated homogeneously ventilated lung
 - APRV extended *time* at inspiration (T_{High}) continually recruits
- Prevent alveolar collapse during expiration
 - APRV very short *time* a expiration (T_{Low}) prevents collapse

The Pressure Time Profile (P/T_p) describes the airway pressure profile of the *Entire Breath* over the time period of one respiratory cycle. P/T_p is the area under the airway pressure curve.





$$P/T_P = \int_{T_{insp}}^{T_{exp}} PdT$$

Two Basic Components of P/T_p

- Pressure
- Time


The Effects of Pressure and Time



Pressure = 40 cm H₂O

Time = 40 seconds

The Pressure Time Profile (P/T_p) describes the airway pressure profile of the *Entire Breath* over the time period of one respiratory cycle. P/T_p is the area under the airway pressure curve.



$$P/T_P = \int_{T_{insp}}^{T_{exp}} P dT$$


Ventilator as a Therapeutic Tool to Prevent ARDS

- Maintain a fully inflated homogeneously ventilated lung
 - APRV extended *time* at inspiration (T_{High}) continually recruits
- Prevent alveolar collapse during expiration
 - APRV very short *time* a expiration (T_{Low}) prevents collapse


Ventilator as a Therapeutic Tool to Prevent ARDS

- Maintain a fully inflated homogeneously ventilated lung
 - APRV extended *time* at inspiration (T_{High}) continually recruits
- Prevent alveolar collapse during expiration
 - APRV very short *time* at expiration (T_{Low}) prevents collapse

T_{Low} Set by a Physiologic Closed Loop Feedback System




APRV



Flow set incorrectly at 10% of Peak Expiratory Flow Rate

APRV



Flow set correctly at 75% of Peak Expiratory Flow Rate

Ventilator as a Therapeutic Tool to Prevent ARDS

- Maintain a fully inflated homogeneously ventilated lung
 - APRV extended *time* at inspiration (T_{High}) continually recruits
- Prevent alveolar collapse during expiration
 - APRV very short *time* a expiration (T_{Low}) prevents collapse

Current Studies in our Lab


Mechanical Breath Profile (MB_p)

Whole Breath Analysis


- Time at Inspiration (T_I)
- Pressure at Inspiration (P_I)
- Time at Expiration (T_E)
- Pressure at Expiration (P_E)
- Transition Time from P_E to P_I (Inspiration rate - ΔP_I)
- Transition Time from P_I to P_E (Expiration rate - ΔP_E)
- Respiratory Rate
- Tidal Volume
- Inspiratory Flow
- Expiratory Flow
- FRC
- TLC

MBp	Time at Insp	Time at Exp	ΔT_E	Press at Insp	Tidal Vol	Q_E
Rho	0.8178	-0.8234	-0.8321	-0.8419	0.1	-0.8763
p value	0.0468	0.0440	0.0398	0.0355	0.0495	0.0220

APRV



Physiologically-based Computational Model







- Short **time** at low pressure with APRV-75% does not allow time for derecruitment
- Long **time** at high pressure with APRV-75% improves lung recruitment
- Thus, APRV-75% opens the lung for homogeneous ventilation and prevents alveolar collapse and instability

Conclusion

- Multiple components in the Mechanical breath including:
 - **Time** a peak inspiration (very long)
 - **Time** at end expiration (very short)
 - Pressure at inspiration (low)
 - Tidal volume (**high**)

Preemptive ventilation to prevent ARDS: Studies from our Lab

Rationale for Prevention



Preemptive Intervention

Present Intervention

SHOCK, Vol. 39, No. 1, pp. 28–38, 2013

**EARLY AIRWAY PRESSURE RELEASE VENTILATION PREVENTS ARDS—A
NOVEL PREVENTIVE APPROACH TO LUNG INJURY**

**Shreyas Roy,* Nader Habashi,[†] Benjamin Sadowitz,* Penny Andrews,[†] Lin Ge,*
Guirong Wang,* Preyas Roy,[‡] Auyon Ghosh,* Michael Kuhn,[§] Joshua Satalin,*
Louis A. Gatto,^{||} Xin Lin,[¶] David A. Dean,[¶] Yoram Vodovotz,** and Gary Nieman***

Our Model: '2-Hit' Peritoneal Sepsis +I/R Induced ARDS



Experimental Design: Surgical Instrumentation

2-Hit Injury

APRV (n=4)

- $P_{\text{high}} = P_{\text{plat}}$
- $P_{\text{low}} = 0$
- $T_{\text{low}} \text{ PEFr} = 75\%$
- $T_{\text{high}} = > 90\% \text{ CPAP}$
- $V_t = 12 \text{ mL/kg}$

Sham (n=5)

- $\text{PEEP} = 5$
- $V_t = 10 \text{ mL/kg}$
- No Sepsis+I/R

ARDSnet (n=3)

- High PEEP Scale
- $V_t = 6 \text{ mL/kg}$
- Applied post $\downarrow \text{O}_2$

Broad Spectrum Antibiotics

Early Goal Directed Therapy Based
Fluid Resuscitation and Vasopressors


All Animals Continuously Monitored
according to ICU Standards of Care

Results


- All Pigs Developed Septic Shock
 - Fever, Leukopenia
 - Hemodynamic Compromise
 - Positive Blood Cultures
 - *E Coli*,
Pseudomonas,
Streptococci,
Klebsiella pneumoniae
- All Pigs Developed Complications of Shock:
 - Abdominal Compartment Syndrome
 - Gastric Stress Ulcers
 - Sepsis Associated Coagulopathy
 - Oliguric Renal Failure

SOFA scores & plasma IL-6 were not different





PaO₂/FiO₂ Ratio




Pressure/Time Profile (P/T_p)



Molecular Protection




Pulmonary Edema



Gross Lung

APRV

ARDSnet




Histopathology


Sham

ARDSnet


APRV



Conclusion: APRV inhibits the Tetrad of ARDS




Appropriate
 P/T_P



Increased Capillary Permeability

Alveolar Edema



Alveolar Instability

Surfactant Deactivation

End of Experiment Ventilator Settings

ARDSnet n=4

Tidal Volume/kg	5.77 ± 0.38
PEEP	20 ± 2.31
FiO2	0.73 ± 0.15

APRV n=4



Tidal Volume/kg	11.98 ± 0.77
Thigh	5.30 ± 0.76
Tlow	0.48 ± 0.03
Phigh	31.00 ± 3.51
Plow	0.0 ± 0.0
FiO2	0.21 ± 0.0

Micro-Anatomical Environment

- Tracheal Tidal Volume (tV_t)
 - V_t delivered by the ventilator to the trachea
- Alveolar Tidal Volume (aV_t)
 - The portion of tV_t delivered to each individual alveoli
- The critical physiologic factor in the development of VILI is not the size of tV_t , but how this tV_t impacts ΔaV_t

Ventilation Near TLC

$V_t = 700 \text{ ml}$





Each Alveolus as to change volume 25%

Inspiration

Expiration


Micro-Anatomical Environment

Vt
700



Micro-Anatomical Environment

Whole Lung Tidal Volume versus Alveolar Tidal Volume in APRV



It is not just the absolute size of the tidal volume but rather the size of the tidal volume in relation to volume of the lung being ventilated

Take an Entirely New Approach

- Deconstruct the mechanical breath
 - Analyze all 10 components of the mechanical breath (pressures, flows, rates, volumes, *Times*)
 - Mechanical Breath Profile (MB_p)
- Determine the impact of any given MB_p on the Micro-environment – the alveoli and alveolar ducts

Impact of the MB_P

Micro-environment

Alveoli and Alveolar Ducts

Research

Original Investigation | ASSOCIATION OF VA SURGEONS


Mechanical Breath Profile of Airway Pressure Release Ventilation

The Effect on Alveolar Recruitment and Microstrain in Acute Lung Injury


Michaela Kollisch-Singule, MD; Bryanna Emr, MD; Bradford Smith, PhD; Shreyas Roy, MD; Sumeet Jain, MD; Joshua Satalin, BS; Kathy Snyder; Penny Andrews, RN; Nader Habashi, MD; Jason Bates, PhD; William Marx, DO; Gary Nieman, BA; Louis A. Gatto, PhD

Kollisch-Singule M, *JAMA Surgery*, In Press

Dynamic Alveolar Strain during Ventilation



Macro- vs Micro-Strain




Conclusions

- APRV 75% both recruits and stabilizes alveoli, preventing collapse during expiration
- APRV 75% minimizes alveolar micro-strain

“Airway Pressure Release Ventilation (APRV) Reduces Conducting Airway micro-Strain in Lung Injury”

Schematic of the Terminal Airway



Inspiration

Expiration

Control

APRV 75%

PEEP 16

PEEP 5

APRV 10%


250 μ m

L.A. Gatto

Normal Lung - SB

ARDS Lungs
MV

Conducting Airway μ -Strain



Conclusions

- The volume of gas in the conducting airways (i.e. ducts) was increased in all lung injured groups.
 - This shift was minimized with APRV 75%
- The volume of gas in the alveoli was reduced in all lung injured groups
 - This shift was minimized with APRV 75%
- Conducting airway micro-strain was minimized with APRV 75%

Lecture Summary

- ARDS is a progressive disease similar to cancer
- Most ARDS develops in the hospital so there is a window of prevention
- Clinical studies have shown that preemptive application of low V_t ventilation to patients with normal lungs, but at high risk, reduces ARDS incidence
- Mechanical injury to the pulmonary parenchyma with inappropriately set mechanical ventilation is a key mechanism driving progressive acute lung injury

Lecture Summary

- In order to scientifically determine how to reduce the mechanical injury caused by MV we must know:
 - The pathologic impact of mechanical injury
 - What components in the mechanical breath (MB_p) are harmful or protective
 - How does any given MB_p impact the Terminal Airway
- We have found that the *Time* pressures and volumes are applied to the lung during each breath are critical for lung protection
- Multiple studies from our lab have shown that preemptive application of appropriately set APRV will block progressive lung damage and prevent ARDS in animals at very high risk

Conclusion

“ARDS is no longer a syndrome that must be treated, but is a syndrome that should be prevented.”

Villar and Slutsky *Critical care*. 2010;14(1):120.

Can the Ventilator be used as a Drug to Prevent ARDS?



Preemptive Ventilation



Waiting for Established-ARDS

Therapeutic Use of Mechanical Ventilation: Can We Change the Way We Manage the Patient?

*2014 Suncoast Pulmonary Symposium
Hyatt Regency Coconut Point Resort
Bonita Springs, Florida
September 10-12, 2014*



Gary F. Nieman

Associate Professor

Department of Surgery

Director,

Cardiopulmonary and Critical Care Laboratory

SUNY Upstate Medical University

Syracuse, NY

Niemang@upstate.edu

UPSTATE
MEDICAL UNIVERSITY